Applications and approvals for new molecular entities (NMEs) in the United States continue to fall ...

... while it continues to dominate R&D spending and total pharmaceutical sales.

- Ken Kostel

Interested in reading more?

Magaizne Cover

Become a Member of

Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member?